Zeo ScientifiX, Inc.

Zeo ScientifiX, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases and regenerative medicine. Its portfolio includes products derived from ethically sourced birth tissue, amniotic fluid, exosomes, Wharton's Jelly matrix, and an autologous biologic platform, with operations centered on manufacturing, commercialization, and related clinical support services.

−102,2 %

82,1 %

−106,2 %

+12,5 %

0.33

0.19

— Zeo ScientifiX, Inc.
%
Biologic therapeutics69% Proprietary biologic products derived from birth tissue, amniotic fluid, and related sources.
Autologous biologic services29% Patient-specific PPX™ processing and service platform using a patient's own blood.
Manufacturing and quality services2% cGMP production, release testing, and related laboratory support for biologic products.

Zeo ScientifiX sells primarily to healthcare providers, including doctors and clinics that administer regenerative...

  • Healthcare providersprimary

    Doctors, clinics, and treatment centers that purchase biologics for in-office use and patient care.

  • Regenerative medicine practicesprimary

    Providers focused on degenerative disease, wound care, pain, and regenerative applications.

  • Aesthetic medicine providerssecondary

    Clinics using allogenic aesthetic biologic products for cosmetic and related procedures.

  • Independent distributorssecondary

    Channel partners that market and distribute the company's products to providers.

  • Clinical collaboration partnersemerging

    Partners involved in manufacturing, regulatory development, and site management for specific programs.

The company is headquartered in Davie, Florida and operates through U.S.-based laboratory and commercial activities...

  • •Headquartered in Davie, Florida
  • •U.S. commercial activity is central to the business model
  • •Manufacturing and lab operations are FDA-registered and cGMP-compliant
  • •Customer and distribution network spans the United States
  • •Disclosures also reference worldwide provider reach

Zeo ScientifiX is focused on expanding commercialization of its biologic portfolio while continuing product development...

01
Expand provider commercializationshort-term

The business depends on provider adoption and repeat use of its biologic products.

02
Develop new biologic offeringsmedium-term

New products can broaden the addressable market and reduce reliance on a narrow product mix.

03
Strengthen collaboration-based executionmedium-term

Partnerships can provide manufacturing capacity, regulatory support, and commercial reach.

The company faces substantial going-concern, funding, and execution risk because its business requires ongoing capital,...

critical

Going-concern and financing dependence

Operations and development require additional capital, and funding may be costly or unavailable.

Scope
Corporate liquidity and ongoing operations
Materiality
high
high

Regulatory and compliance risk

Products are biologics subject to FDA oversight, HCT/P enforcement, and cGMP requirements.

Scope
Product approval, commercialization, and manufacturing
Materiality
high
high

Competitive pressure

Larger competitors may have stronger brands, capital, and distribution, pressuring pricing and share.

Scope
Allogenic biologics and regenerative medicine products
Materiality
high
high

Internal control weaknesses

Material weaknesses can impair financial reporting reliability and investor confidence.

Scope
Financial statements and disclosure controls
Materiality
high
medium

Supply concentration and third-party dependence

Raw materials and supplies are sourced from unaffiliated laboratories and could be disrupted.

Scope
Manufacturing continuity and product availability
Materiality
medium
medium

Intellectual property protection

Commercial success depends on patents and proprietary processing techniques.

Scope
Zofin™, PPX™, and related biologic platforms
Materiality
medium
Revenue recognition by product vs. service
Affects revenue timing, gross margin, and comparability
Stock-based compensation
Can materially increase operating expenses
Going-concern and asset recoverability
May lead to impairment or write-down risk
Internal control and disclosure estimates
Affects reliability of financial statements

Zivo Bioscience, Inc.

ZIVO · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

MIMEDX GROUP, INC.

MDXG · Surgical & Medical Instruments & Apparatus

EXOZYMES INC.

EXOZ · Biological Products, (No Diagnostic Substances)

Xenetic Biosciences, Inc.

XBIO · Pharmaceutical Preparations

SANGAMO THERAPEUTICS, INC

SGMOQ · Biological Products, (No Diagnostic Substances)

: 29/04/2026